Core A is essential to the success of the SPORE and provides oversight and support of all SPORE projects and activities;ensures compliance with all general, governmental, and National Cancer Institute (NCI)/National Institutes of Health (NIH) regulations and requirements;coordinates communications and consultations with the NCI project officer and other NCI staff in preparing all required reports and publications;coordinates all SPORE-related meetings and communications of the Executive Committee, Internal and External Advisory Boards, the Biostatistics and Data Management Core (Core B), and the Tissue Procurement, Pathology and Biomarker Core (Core C);and other key functions. Over the previous grant period, Core A oversaw the annual budget/rebudget development, distribution, and oversight of grant funds;supported the Executive Committee and advisory boards in scheduling and coordinating regularly scheduled meetings and ad hoc consultations;coordinated the annual solicitation, review, and award process for the Career Development and the Developmental Research Programs;served as the primary liaison in developing potential InterSPORE collaborations and with the NCI SPORE program representatives; and interacted on a regular basis with Core Directors and Project Leaders to review progress, identify problems, and resolve issues hampering successful achievement of their aims. The past trial activation and accrual record of this HN SPORE was the appropriate target of criticism in our previous review;thus, the SPORE leadership team has implemented several mechanisms to enhance the oversight, and thus activation and accrual, of our SPORE clinical trials, including 1) quarterly accrual report submissions to the Executive Committee (and more frequently should concerns arise);quarterly presentations by the Pis of the SPORE trials to the Executive Committee on accrual progress;annual review of all trials by the Internal and External Advisory Boards;and a requirement to address accrual deficiencies within six-months or risk study closure or replacement. Major SPORE and Core A leadership changes occurred in the fall of 2006, when Dr. Scott M. Lippman succeeded Dr. Waun Ki Hong as SPORE PI and Core A Director and Dr. Rakesh Kumar succeeded Dr. Reuben Lotan as a SPORE Co-Pi and Core A Co-Director (sharing these roles with Dr. Gary L. dayman, who continues a Co-Pi and Co-Director from the previous grant period). The experienced leadership of the HN SPORE will ensure full compliance with all policies and procedures required of NCIand NIH-funded research programs to successfully achieve the SPORE's overall aims.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097007-09
Application #
8310822
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
9
Fiscal Year
2011
Total Cost
$172,155
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Zhang, Hua; Sturgis, Erich; Zhu, Lijun et al. (2018) The Modifying Effect of a Functional Variant at the miRNA Binding Site in E2F1 Gene on Recurrence of Oropharyngeal Cancer Patients with Definitive Radiotherapy. Transl Oncol 11:633-638
Gleber-Netto, Frederico O; Zhao, Mei; Trivedi, Sanchit et al. (2018) Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer 124:84-94
(2018) Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet 50:668-681
Jurkovic, Ines-Ana; Kocak-Uzel, Esengul; Mohamed, Abdallah Sherif Radwan et al. (2018) Dosimetric and Radiobiological Evaluation of Patient Setup Accuracy in Head-and-neck Radiotherapy Using Daily Computed Tomography-on-rails-based Corrections. J Med Phys 43:28-40
Huckins, L M; Hatzikotoulas, K; Southam, L et al. (2018) Investigation of common, low-frequency and rare genome-wide variation in anorexia nervosa. Mol Psychiatry 23:1169-1180
M. D. Anderson Cancer Center Head and Neck Quantitative Imaging Working Group (2018) Investigation of radiomic signatures for local recurrence using primary tumor texture analysis in oropharyngeal head and neck cancer patients. Sci Rep 8:1524
Gadhikar, Mayur A; Zhang, Jiexin; Shen, Li et al. (2018) CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Res 78:781-797
Zhang, Tongwu; Choi, Jiyeon; Kovacs, Michael A et al. (2018) Cell-type-specific eQTL of primary melanocytes facilitates identification of melanoma susceptibility genes. Genome Res 28:1621-1635
Saintigny, Pierre; Mitani, Yoshitsugu; Pytynia, Kristen B et al. (2018) Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer 124:3693-3705
Pinnix, Chelsea C; Ng, Andrea K; Dabaja, Bouthaina S et al. (2018) Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv 2:1334-1343

Showing the most recent 10 out of 370 publications